Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.12 USD | +4.95% | -4.93% | -89.65% |
May. 16 | Evercore ISI Adjusts Price Target on AN2 Therapeutics to $2 From $7, Maintains In-Line Rating | MT |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 60.25M |
---|---|---|---|---|---|
Net income 2024 * | -75M | Net income 2025 * | -91M | EV / Sales 2024 * | - |
Net cash position 2024 * | 59.8M | Net cash position 2025 * | 101M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.87
x | P/E ratio 2025 * |
-0.89
x | Employees | 41 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.83% |
1 day | +4.95% | ||
1 week | -4.93% | ||
Current month | -11.67% | ||
1 month | -8.62% | ||
3 months | -28.86% | ||
6 months | -87.09% | ||
Current year | -89.65% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 17-01-31 | |
Eric Easom
FOU | Founder | 56 | 17-01-31 |
Lucy Day
DFI | Director of Finance/CFO | 65 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 60 | 17-01-31 | |
Patricia Martin
BRD | Director/Board Member | 63 | 21-03-31 |
Melvin Spigelman
BRD | Director/Board Member | 75 | 22-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +10.17% | - | |
0.00% | 17 M€ | +5.25% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 2.12 | +4.95% | 119,821 |
24-05-24 | 2.02 | +0.50% | 182,436 |
24-05-23 | 2.01 | -5.19% | 208,404 |
24-05-22 | 2.12 | -2.08% | 115,283 |
24-05-21 | 2.165 | -2.91% | 78,832 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-89.65% | 60.25M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- ANTX Stock